Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Receivables: 2024

Historic Change in Receivables for ARS Pharmaceuticals (SPRY) over the last 1 years, with Dec 2024 value amounting to $8.2 million.

  • ARS Pharmaceuticals' Change in Receivables rose 1712.03% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year change of. This contributed to the annual value of $8.2 million for FY2024, which is N/A change from last year.
  • ARS Pharmaceuticals' Change in Receivables amounted to $8.2 million in FY2024.
  • ARS Pharmaceuticals' 5-year Change in Receivables high stood at $8.2 million for FY2024, and its period low was $8.2 million during FY2024.
  • For the 1-year period, ARS Pharmaceuticals' Change in Receivables averaged around $8.2 million, with its median value being $8.2 million (2024).